NHE1 Drives Octanal/Olfr2-Induced Atherosclerosis via Inflammation

Study Background and Research Question

Atherosclerosis (AS) remains the leading cause of cardiovascular morbidity and mortality worldwide, primarily through its role in promoting plaque formation and arterial dysfunction. Macrophages, central to the pathogenesis of AS, contribute to plaque growth by engulfing lipids and forming foam cells, as well as by orchestrating inflammatory responses. Despite advances in lipid-lowering therapies and vascular interventions, a substantial residual risk persists in affected populations, motivating the search for novel molecular contributors to disease progression. Recent attention has focused on non-canonical roles for olfactory receptors in immune cells, particularly Olfr2 in vascular macrophages, which recognize endogenous metabolites like octanal and trigger inflammatory cascades. The reference study (Wang et al., 2025) investigates the interplay between octanal/Olfr2 signaling and sodium-hydrogen exchanger 1 (NHE1) in macrophages, probing their joint impact on atherogenesis and inflammation.

Key Innovation from the Reference Study

The central innovation of the reference paper lies in identifying NHE1 as a critical downstream effector of octanal/Olfr2 signaling in macrophages during atherosclerotic progression. While previous studies established that Olfr2 detects the lipid peroxidation product octanal and contributes to vascular inflammation, the precise molecular mediators linking this receptor to plaque formation were incompletely characterized. Wang et al. demonstrate that NHE1 upregulation in response to octanal is not merely correlative but functionally required for calcium-dependent reactive oxygen species (ROS) production and subsequent NLRP3 inflammasome activation. This mechanistic insight positions NHE1 as a potential therapeutic target for controlling macrophage-driven inflammation in AS.

Methods and Experimental Design Insights

The research approach combined in vivo and in vitro systems to rigorously dissect the signaling axis. ApoE^−/− mice, a well-established model for atherosclerosis, were administered intraperitoneal octanal to simulate elevated endogenous ligand exposure. Plaque formation and inflammatory markers were quantified, and NHE1 expression in macrophages was assessed via histology and molecular assays. In parallel, RAW264.7 macrophage cultures were treated with octanal and a selective NHE1 inhibitor, enabling dose- and time-dependent evaluation of NHE1 activity, foam cell formation, and inflammatory cytokine production. The team further deployed RNA interference to knock down Olfr2 and applied calcium chelators to interrogate the requirement for calcium influx in this pathway. Collectively, these methods provided both correlative and causative evidence for the NHE1-dependent inflammatory cascade.

Protocol Parameters

• Animal model: ApoE^−/− mice, standard for atherosclerosis research; octanal administered intraperitoneally to induce plaque formation and simulate endogenous ligand exposure.
• Macrophage culture: RAW264.7 cell line, treated with graded concentrations of octanal to assess dose- and time-dependent effects on NHE1 expression and inflammatory responses.
• NHE1 inhibition: Application of a selective NHE1 inhibitor (e.g., cariporide) to dissect downstream signaling requirements.
• RNA interference: Silencing of Olfr2 to establish its necessity upstream of NHE1 activation.
• Calcium chelation: Use of Ca²⁺ chelators (e.g., BAPTA-AM) to clarify the calcium dependence of ROS and inflammasome activation.

Core Findings and Why They Matter

The study's results reveal that octanal administration in ApoE^−/− mice aggravates atherosclerosis by upregulating NHE1 in macrophages within plaques, with genetic or pharmacologic inhibition of NHE1 significantly reducing plaque burden and inflammatory cytokine levels (see original study). In vitro, octanal induced NHE1 expression and activity in RAW264.7 cells, promoting foam cell formation and pro-inflammatory cytokine release. Importantly, these effects were mitigated by NHE1 inhibitors and by RNAi-mediated Olfr2 knockdown, confirming the hierarchical relationship between olfactory receptor signaling and NHE1 function. Calcium chelation further suppressed downstream ROS production and NLRP3 inflammasome activation, cementing the role of calcium flux in this process. These findings collectively suggest that NHE1 is indispensable for translating octanal/Olfr2 signals into the oxidative and inflammatory events that drive plaque progression, providing a mechanistic rationale for targeting NHE1 in therapeutic strategies.

From a technical standpoint, these data directly relate to the challenge of reducing non-specific antibody binding and improving antibody stability in assays, as robust detection of NHE1 and associated inflammatory markers in Western blotting and immunoassays is essential to validate such mechanistic studies. The reliability of protein detection in these workflows is tightly linked to the effectiveness of secondary antibody dilution buffers, which reduce background and enhance specific signal.

Comparison with Existing Internal Articles

Several internal articles corroborate and expand upon these findings. For instance, NHE1 Drives Octanal/Olfr2-Mediated Atherosclerosis via Inflammatory Pathways and NHE1 in Macrophages Drives Octanal/Olfr2-Induced Atherosclerosis both emphasize the centrality of NHE1 in mediating the pro-atherogenic effects of octanal-activated Olfr2 signaling. These resources highlight the calcium-dependent generation of ROS and activation of the NLRP3 inflammasome as convergent endpoints, fully consistent with the reference study. Notably, these internal articles underscore NHE1 as a viable target for interventions aimed at modulating inflammatory responses in cardiovascular disease, mirroring the implications of Wang et al. The consistency across reference and internal literature strengthens the mechanistic model and provides a foundation for further translational research.

Limitations and Transferability

While the reference study offers compelling evidence for the role of NHE1 in atherosclerosis, several limitations merit consideration. The bulk of the experimental data derives from murine models (ApoE^−/− mice) and the RAW264.7 macrophage cell line, which, despite being well-established systems, may not fully recapitulate the complexity of human disease. The translation of these findings to human atherosclerosis requires confirmation in primary human macrophages and clinical samples. Additionally, the use of pharmacologic inhibitors and RNA interference introduces potential off-target effects, although the convergence of genetic and pharmacologic evidence strengthens causal inference. The study does not address the long-term consequences or potential compensatory responses following sustained NHE1 inhibition in vivo, which are important for therapeutic development. Finally, while the data robustly link NHE1 to ROS and inflammasome activation, downstream consequences on plaque stability and clinical endpoints remain to be explored in future research.

Research Support Resources

Reproducible detection of NHE1 and inflammatory markers in protein assays is critical for validating mechanistic models such as those described in Wang et al. To support these workflows, researchers can utilize the Western Secondary Antibody Dilution Buffer (SKU K4115) from APExBIO, which is formulated to optimize secondary antibody dilution for Western blot applications. This buffer is specifically designed to minimize background by reducing non-specific antibody binding while enhancing the stability and reusability of diluted antibodies, thereby improving the clarity and reliability of protein detection Western blot results. For those seeking robust and cost-effective solutions in protein quantification and immunoassay development, incorporating a high-quality secondary antibody dilution buffer may help ensure consistent results across multiple experimental replicates.